leadf
logo-loader
viewVectura Group PLC

Vectura hikes guidance after approval of a generic Advair and CDMO wins

A US$200m patent litigation win against GlaxoSmithKline is expected to be mostly paid by the end of this month

Vectura Group PLC -

Vectura Group PLC (LON:VEC) said sales and profits for 2020 will be better than the market expects, after the approval of a generic version of asthma drug Advair in December.

This US regulatory approval led to an US$11mln milestone payment from partner Hikma.

Moreover, the drug formulation specialist said it has won 18 contracts under its inhalation contract development and manufacturing organization (CDMO) strategy, with roughly £3mln of revenue from this new business being recognised in the second half of the year.

Management said they expect CDMO revenue to more than treble in 2021, while also anticipating £5-7mln of operating expenditure savings from a planned site closure in Switzerland, offset by some “low single-digit millions” of exceptional cash costs from the transition towards a development services model.

Vectura said it closed the year with cash and equivalents of roughly £79mln, versus £81.9mln at the half year.

A previously announced US$200m patent litigation win against GlaxoSmithKline is expected to be mostly paid by the end of this month and subject to 10% tax.

Quick facts: Vectura Group PLC

Price: 119.678 GBX

AIM:VEC
Market: AIM
Market Cap: £713.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

JPD Capital and Verdex Group join forces in premium medicinal cannabis...

John-Paul Doran, CEO & Founder of JPD Capital is joined by Adam Dignan, Founder and CEO Verdex Group to explain their latest collaboration - Ibero Botanica.  Doran explains to Proactive's Katie Pilbeam, Verdex 'encapsulates all of the traits that we were looking for' in regards to...

1 hour, 13 minutes ago

2 min read